Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill StudyZacks Investment Research • 08/20/25
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'Benzinga • 08/19/25
Viking Therapeutics shares plunge on weight loss trial tolerability concernsProactive Investors • 08/19/25
Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study SuccessSeeking Alpha • 08/19/25
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial dataCNBC • 08/19/25
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock TanksBenzinga • 08/19/25
Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.Market Watch • 08/19/25
Viking Therapeutics Crashes 41% On Mixed Results For Its Weight-Loss PillInvestors Business Daily • 08/19/25
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesityPRNewsWire • 08/19/25
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 08/12/25
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 08/04/25